presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

The Commissioner has determined for the reasons stated that those portions of the advisory committee meetings so designated in this notice shall be closed. The Federal Advisory Committee Act (FACA) (5 U.S.C. app. 2, 10(d)), permits such closed advisory committee meetings in certain circumstances. Those portions of a meeting designated as closed, however, shall be closed for the shortest possible time, consistent with the intent of the cited statutes.

The FACA, as amended, provides that a portion of a meeting may be closed where the matter for discussion involves a trade secret; commercial or financial information that is privileged or confidential; information of a personal nature, disclosure of which would be a clearly unwarranted invasion of personal privacy; investigatory files compiled for law enforcement purposes; information the premature disclosure of which would be likely to significantly frustrate implementation of a proposed agency action; and information in certain other instances not generally relevant to FDA matters.

Examples of portions of FDA advisory committee meetings that ordinarily may be closed, where necessary and in accordance with FACA criteria, include the review, discussion, and evaluation of drafts of regulations or guidelines or similar preexisting internal agency documents, but only if their premature disclosure is likely to significantly frustrate implementation of proposed agency action; review of trade secrets and confidential commercial or financial information submitted to the agency; consideration of matters involving investigatory files compiled for law enforcement purposes; and review of matters, such as personnel records or individual patient records, where disclosure would constitute a clearly unwarranted invasion of personal privacy.

Examples of portions of FDA advisory committee meetings that ordinarily shall not be closed include the review, discussion, and evaluation of general preclinical and clinical test protocols and procedures for a class of drugs or devices; consideration of labeling requirements for a class of marketed drugs or devices; review of data and information on specific investigational or marketed drugs and devices that have previously been made public; presentation of any other data or information that is not exempt from public disclosure pursuant to the FACA, as amended; and, deliberation to formulate advice and recommendations to the agency on matters that do not independently justify closing.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: March 29, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–8246 Filed 4–3–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95P–0110]

Guidance Documents; The Food and Drug Administration's Development and Use; Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public meeting on issues relating to the agency's development and use of guidance documents. The agency is holding this public meeting to further discuss issues that were raised in a citizen petition submitted by the Indiana Medical Devices Manufacturers Council, Inc. (IMDMC). The citizen petition requested that FDA control the development of guidance documents by written procedures that ensure the appropriate level of meaningful public participation.

DATES: The public meeting will be held on Friday, April 26, 1996, 9 a.m. to 3 p.m.

ADDRESSES: The public meeting will be held at the National Institutes of Health, Warren Grant Magnuson Clinical Center, Bldg. 10, Masur Auditorium, 9000 Rockville Pike, Bethesda, MD 20892–1162. Those persons interested in attending this meeting should FAX their registration to Lisa Barclay by April 16, 1996.

The notice of registration should include the registrant's name, address, telephone number, FAX number, and business affiliation, if any. Persons interested in making a presentation at the meeting should include a brief summary of the presentation, and the approximate amount of time requested for the presentation. FDA will allocate the time available for the public meeting among the persons who properly file notices of their intent to make a presentation at the meeting. If time permits, FDA may allow additional presentations from interested persons attending the meeting who did not submit a notice of their intent to make a presentation.

Notices of registration should be received by April 16, 1996. There is no registration fee for this public meeting, but advance registration is required. Interested parties are encouraged to register early.

Parking in the Clinical Center visitor area is reserved for Clinical Center patients and their visitors. If you must drive, please use an outlying parking lot, such as Lot 41B. Free shuttle bus service is provided from Lot 41B to the Clinical Center every 8 minutes during rush hour and every 15 minutes at other times. The National Institutes of Health campus may be reached by subway (Metro). Take the Red Line to the Medical Center stop. The same shuttle service is available from Metro to the Clinical Center.

FOR FURTHER INFORMATION CONTACT: Lisa Barclay, Office of Policy (HF–23), Food and Drug Administration, 5600 Fishers Lane, rm. 14–101, Rockville, MD 20857, 301–827–3360, FAX 301–594–6777.

SUPPLEMENTARY INFORMATION: Issues relating to FDA's development and use of guidance documents were raised in a citizen petition submitted by the IMDMC. (See Docket No. 95P–0110). Specifically, the petition requested that FDA control the initiation, development, and issuance of guidance documents by written procedures that ensure the appropriate level of

meaningful public participation. FDA agreed to take steps to improve its guidance document procedures. In the Federal Register of March 7, 1996 (61 FR 9181), FDA published a notice that sets forth its current thinking on ways to improve its guidance document procedures and solicited comment on these and additional ideas for improvement. The purpose of this public meeting is to further discuss the issues set forth in the notice published in the Federal Register of March 7, 1996 (61 FR 9181).

Dated: March 29, 1996.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 96–8359 Filed 4–1–96; 3:25 pm]

BILLING CODE 4160–01–F

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–3919–N–02]

Office of the Assistant Secretary for Public and Indian Housing; Notice of Proposed Information Collection for Public Comment

AGENCY: Office of the Assistant Secretary for Public and Indian Housing, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: *Comments due:* June 3, 1996.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Mildred M. Hamman, Reports Liaison Officer, Public and Indian Housing, Department of Housing and Urban Development, 451—7th Street, SW, Room 4255, Washington, D.C. 20410–5000.

FOR FURTHER INFORMATION CONTACT: Mildred M. Hamman, (202) 708–0846, for copies of the proposed forms and other available documents. (This is not a toll-free number).

SUPPLEMENTARY INFORMATION: The Department will submit the proposed information collection to OMB for review, as required by the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended).

This Notice is soliciting comments from members of the public and affected agencies concerning the proposed collection of information to: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information; (3) enhance the quality, utility, and clarity of the information to be collected; and (4) minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated collection techniques or other forms of information technology; e.g., permitting electronic submission of responses.

This Notice also lists the following information:

Title of Proposal: Public and Indian Housing—Life Cycle Cost Analysis of Utility Combinations in Public Housing.

OMB Control Number: 2577–0024.

Description of the Need for the Information and Proposed Use: The U.S. Housing Act of 1937, as amended, requires that, to the maximum extent practicable, newly constructed and substantially rehabilitated developments assisted under the Act be equipped with heating and cooling systems selected on the basis of criteria which include a life-cycle cost analysis of such systems. The Housing and Community Development Act of 1980 requires these developments to be equipped with a passive or active solar energy system that would be cost effective over the estimated life of the system to be installed. The life-cycle cost analysis of utility combinations (LCCAUC) is necessary to compare and recommend the most cost-effective utility-combination for new constructions or rehabilitation projects.

Agency Form Number: HUD–51994 (Optional).

Members of Affected Public: PHAs; IHAs.

Estimation of the Total Number of Hours Needed To Prepare the Information Collection Including Number of Respondents, Frequency of Response, and Hours of Response: 238 respondents, one occasion for each (a) newly constructed development, (b) substantially rehabilitated development or (c) moderninzation project involving a change in utility combination, 6.0 average hours per response, 1,428 total burden hours.

Status of the Proposed Information Collection: Reinstatement of a Previously Approved Collection for Which Approval has Expired.

Authority: Section 3506 of the Paperwork Reduction Act of 1995, 44 U.S.C. Chapter 35, as amended.

Dated: March 27, 1996.

Michael B. Janis,

General Deputy Assistant Secretary for Public and Indian Housing.

BILLING CODE 4210–33–M